<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539470</url>
  </required_header>
  <id_info>
    <org_study_id>GA41825</org_study_id>
    <nct_id>NCT04539470</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>A Phase Ib, Open-Label, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase Ib, open-label, multicenter, dose-escalation study to evaluate the safety,&#xD;
      tolerability, and pharmacokinetics of Efmarodocokin Alfa and to make a preliminary assessment&#xD;
      of activity of Efmarodocokin Alfa in combination with standard-of-care (SOC) in the&#xD;
      prevention of acute graft-versus-host disease (aGVHD) in participants undergoing allogeneic&#xD;
      hematopoietic stem cell transplantation (HSCT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">April 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 17, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI-CTCAE v5.0)</measure>
    <time_frame>From Baseline up to 365 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Respiratory Rate Over Time</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Oxygen Saturation Over Time</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Pulse Rate Over Time</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Systolic Blood Pressure Over Time</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Diastolic Blood Pressure Over Time</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Body Temperature Over Time</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Laboratory Abnormalities in Hematology Tests</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Laboratory Abnormalities in Blood Chemistry Tests</measure>
    <time_frame>From Baseline up to 139 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Efmarodocokin Alfa at Specified Timepoints</measure>
    <time_frame>At predefined timepoints from Baseline until Day 139</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Drug Antibodies (ADAs) at Baseline and During the Study</measure>
    <time_frame>At predefined timepoints from Baseline until Day 139</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Cohort A: Efmarodocokin Alfa Dosage Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Efmarodocokin Alfa Dosage Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: Efmarodocokin Alfa Dosage Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efmarodocokin Alfa</intervention_name>
    <description>Efmarodocokin Alfa will be administered intravenously (IV) per the dosage specified in each dose escalation cohort.</description>
    <arm_group_label>Cohort A: Efmarodocokin Alfa Dosage Level 1</arm_group_label>
    <arm_group_label>Cohort B: Efmarodocokin Alfa Dosage Level 2</arm_group_label>
    <arm_group_label>Cohort C: Efmarodocokin Alfa Dosage Level 3</arm_group_label>
    <other_name>UTTR1147A</other_name>
    <other_name>RG7880</other_name>
    <other_name>RO7021610</other_name>
    <other_name>IL-22Fc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible for hematopoietic stem cell transplantation (HSCT)&#xD;
&#xD;
          -  Donor meeting human leukocyte antigen (HLA) matching criteria of HLA-matched related&#xD;
             or HLA-matched unrelated (HLA-A, HLA-B, HLA-C, and HLA-DRB1, eight out of eight) from&#xD;
             either peripheral blood or bone marrow stem cells and meeting donor-eligibility&#xD;
             criteria as outlined by the U.S. Food and Drug Administration (FDA) in 21 CFR 1271&#xD;
             (including screening for Zika and SARS-CoV-2 exposure or infection)&#xD;
&#xD;
          -  Planned HLA (HLA-A, HLA-B, HLA-C, and HLA-DRB1)-matched (eight out of eight) related&#xD;
             or planned HLA-matched (eight out of eight) unrelated HSCT, from either peripheral&#xD;
             blood or bone marrow stem cells, for patients with acute myeloid leukemia (AML) or&#xD;
             acute lymphocytic leukemia (ALL) in first complete remission (per institutional&#xD;
             criteria) or patients with intermediate or high-risk myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  Planned myeloablative conditioning regimen per institutional guidelines&#xD;
&#xD;
          -  Planned aGvHD prophylaxis consisting of tacrolimus and methotrexate; in cases of&#xD;
             tacrolimus intolerance, cyclosporine or sirolimus may be used as a substitute&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior receipt of autologous or allogeneic HSCT&#xD;
&#xD;
          -  Diagnosis of myelofibrosis or myelodysplastic/myeloproliferative overlap syndrome&#xD;
&#xD;
          -  Treatment with investigational biologic or non-biologic therapy within 5 drug&#xD;
             elimination half-lives (or within 90 days or 30 days, respectively, if half-life is&#xD;
             unknown) prior to initiation of study drug&#xD;
&#xD;
          -  Positive hepatitis B virus (HBV) or hepatitis C virus (HCV) serologies&#xD;
&#xD;
          -  History of Grade &gt;1 cervical intraepithelial neoplasia&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval&#xD;
&#xD;
          -  Risk factors for torsades de pointes&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Any serious medical condition or abnormality in clinical laboratory tests that, in the&#xD;
             investigator's judgment, precludes the patient's safe participation in and completion&#xD;
             of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GA41825 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine; Clinical Reseach Building</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Med Ctr; Int med/Allgy/Immun/Rheum</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160-7350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).&#xD;
For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

